search
Back to results

Rheos Feasibility Trial

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Implantation of the Rheos System
Standard of care medical management
Sponsored by
CVRx, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be at least 21 years of age.
  2. Have been assessed to have bilateral carotid bifurcations located at or below C3-C4.
  3. Have an office cuff systolic blood pressure greater than or equal to 160 mmHg and a 24-hour ambulatory systolic blood pressure greater than or equal to 150 mmHg despite at least one month of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic.
  4. Must be certified by the investigator hypertension specialist as compliant with taking full doses of medication.
  5. Have signed a CVRx approved informed consent for participation in this study.

Exclusion Criteria:

  1. Have been diagnosed with:

    • Baroreflex failure
    • Cardiac bradyarrhythmias
    • Chronic atrial fibrillation
  2. Had a heart transplant
  3. Have carotid atherosclerosis producing a 50% or greater reduction in linear diameter as determined by ultrasound or angiographic evaluation as determined within six months of enrollment in the trial.
  4. Have Grade C ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation.
  5. Have prior surgery or radiation in either carotid sinus region.
  6. Currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems.
  7. Are pregnant or contemplating pregnancy during the 13-month follow-up period.
  8. Currently undergoing dialysis.
  9. Have hypertension secondary to a treatable cause.
  10. Have clinically significant cardiac valvular disease.
  11. Are unable or unwilling to fulfill the protocol medication compliance and follow-up requirements.
  12. Are unlikely to survive the protocol follow-up period.
  13. Are enrolled in another concurrent clinical trial.

    -

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Rheos Device

    Medical Management

    Arm Description

    Outcomes

    Primary Outcome Measures

    Rheos Feasibility Study
    To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant). To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious sytem related event-free rate through 4 and 13 months post-implant.

    Secondary Outcome Measures

    Full Information

    First Posted
    February 25, 2010
    Last Updated
    June 28, 2019
    Sponsor
    CVRx, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01077180
    Brief Title
    Rheos Feasibility Trial
    Official Title
    Rheos Feasibility Trial- A Study of Baroreflex Hypertension TherapyTM in Refractory Hypertension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2005 (undefined)
    Primary Completion Date
    December 2007 (Actual)
    Study Completion Date
    October 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    CVRx, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The Rheos Feasibility Trial is designed to assess safety, device performance, and protocol parameters of the CVRx Rheos Baroreflex Therapy in patients with severe hypertension that are refractory to full drug therapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    16 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Rheos Device
    Arm Type
    Experimental
    Arm Title
    Medical Management
    Arm Type
    Active Comparator
    Intervention Type
    Device
    Intervention Name(s)
    Implantation of the Rheos System
    Intervention Description
    Open label
    Intervention Type
    Other
    Intervention Name(s)
    Standard of care medical management
    Intervention Description
    Patients will continue with medical therapy for standard of care of their hypertension.
    Primary Outcome Measure Information:
    Title
    Rheos Feasibility Study
    Description
    To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant). To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious sytem related event-free rate through 4 and 13 months post-implant.
    Time Frame
    13 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Be at least 21 years of age. Have been assessed to have bilateral carotid bifurcations located at or below C3-C4. Have an office cuff systolic blood pressure greater than or equal to 160 mmHg and a 24-hour ambulatory systolic blood pressure greater than or equal to 150 mmHg despite at least one month of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic. Must be certified by the investigator hypertension specialist as compliant with taking full doses of medication. Have signed a CVRx approved informed consent for participation in this study. Exclusion Criteria: Have been diagnosed with: Baroreflex failure Cardiac bradyarrhythmias Chronic atrial fibrillation Had a heart transplant Have carotid atherosclerosis producing a 50% or greater reduction in linear diameter as determined by ultrasound or angiographic evaluation as determined within six months of enrollment in the trial. Have Grade C ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation. Have prior surgery or radiation in either carotid sinus region. Currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems. Are pregnant or contemplating pregnancy during the 13-month follow-up period. Currently undergoing dialysis. Have hypertension secondary to a treatable cause. Have clinically significant cardiac valvular disease. Are unable or unwilling to fulfill the protocol medication compliance and follow-up requirements. Are unlikely to survive the protocol follow-up period. Are enrolled in another concurrent clinical trial. -

    12. IPD Sharing Statement

    Learn more about this trial

    Rheos Feasibility Trial

    We'll reach out to this number within 24 hrs